ATMP2030

Finalized
Category: Ecosystem Coordination Funding: VINNOVA

SYSTEM TRANSFORMATION TO MAKE SWEDEN WORLD LEADING IN ATMP BY 2030

The project aims to establish a ‘Vision Driven Innovation Milieu’ for long-term transformation of the systems required for successful development and implementation of advanced therapy gene and cell therapeutic products, Advanced Therapy Medicinal Products (ATMP). ATMP2030 will be an inclusive platform with a common vision that brings together relevant stakeholders. This project is based on the Vinnova Vision Driven Health program. Important intermediate goals are a national pool of power and increased internationalization, better conditions for the development and accessibility of advanced therapies, as well as increased knowledge of the area to secure future competence needs.

Coordinator: RISE Research Institutes of Sweden AB – RISE Bioscience and Materials

SUBGOALS

  • National coordination and strengthening of the network, as well as increased international contacts and collaborations
  • Increased capacity for industrial development and manufacture of ATMPs in Sweden
  • Effective processes for availability of cost-effective ATMPs within Swedish healthcare
  • Increase knowledge and secure future competence needs
  • Organization and financing model for sustainable continuation

Working to make ‘Sweden a world leader in development and implementation of advanced therapies by 2030’

Contact: Jennifer Rosendahl

Partners

Akademiska Sjukhuset
Apotekarsocieteten
Astra Zeneca
CombiGene
Mendus
Karolinska Universitetssjukhuset
Läkemedelsakademin
LIF
Läkemedelsverket
MSC Nordics
NextCell Pharma
Region Skåne
Region Västerbotten
Region Örebro
Region Östergötland
SKR
Umeå universitet
VERIGRAFT
Västra Götalandsregionen
XNK Therapeutics